Pharmacokinetics and skin concentrations of lincomycin after intravenous and oral administration to cats

Autores
Albarellos, Gabriela Alejandra; Montoya, Laura; Denamiel, Graciela A. A.; Passini, Sabrina Mariela; Landoni, Maria Fabiana
Año de publicación
2013
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The aim of the present study was to describe the plasma pharmacokinetic profile and skin concentrations of lincomycin after intravenous administration of a 15% solution and oral administration of 300 mg tablets at a dosing rate of 15 mg/kg to cats. Susceptibility of staphylococci (n = 31) and streptococci (n = 23) strains isolated from clinical cases was also determined. Lincomycin plasma and skin concentrations were determined by microbiological assay using Kocuria rhizophila ATCC 9341 as test microorganism. Susceptibility was established by the antimicrobial disc diffusion test. Individual lincomycin plasma concentration-time curves were analysed by a non-compartmental approach. After intravenous administration, volume of distribution, body clearance and elimination half-life were 0.97 L/kg ± 0.15 L/kg, 0.17 L/kg ± 0.06 L/h.kg and 4.20 h ± 1.12 h, respectively. After oral administration, peak plasma concentration, time of maximum plasma concentration and bioavailability were 22.52 μg/mL ± 10.97 μg/mL, 0.80 h ± 0.11 h and 81.78% ± 24.05%, respectively. Two hours after lincomycin administration, skin concentrations were 17.26 μg/mL ± 1.32 μg/mL (intravenous) and 16.58 μg/mL ± 0.90 μg/mL (oral). The corresponding skin: plasma ratios were 2.08 ± 0.47 (intravenous) and 1.84 ± 0.97 (oral). The majority of staphylococci and streptococci tested in this study were susceptible to lincosamides (87.09% and 69.56%, respectively). In conclusion, lincomycin administered orally at the assayed dose showed a good pharmacokinetic profile, with a long elimination half-life and effective skin concentration. Therefore, it could be a good first option for treating skin infections in cats.
Fil: Albarellos, Gabriela Alejandra. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; Argentina
Fil: Montoya, Laura. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; Argentina
Fil: Denamiel, Graciela A. A.. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; Argentina
Fil: Passini, Sabrina Mariela. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; Argentina
Fil: Landoni, Maria Fabiana. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina
Materia
LINCOMYCIN
PHARMACOKINETICS
SKIN
CAT
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/77377
Acceder
id CONICETDig_31abe3d4628a00cc830a8ad639ee6c48
oai_identifier_str oai:ri.conicet.gov.ar:11336/77377
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Pharmacokinetics and skin concentrations of lincomycin after intravenous and oral administration to catsAlbarellos, Gabriela AlejandraMontoya, LauraDenamiel, Graciela A. A.Passini, Sabrina MarielaLandoni, Maria FabianaLINCOMYCINPHARMACOKINETICSSKINCAThttps://purl.org/becyt/ford/4.3https://purl.org/becyt/ford/4The aim of the present study was to describe the plasma pharmacokinetic profile and skin concentrations of lincomycin after intravenous administration of a 15% solution and oral administration of 300 mg tablets at a dosing rate of 15 mg/kg to cats. Susceptibility of staphylococci (n = 31) and streptococci (n = 23) strains isolated from clinical cases was also determined. Lincomycin plasma and skin concentrations were determined by microbiological assay using Kocuria rhizophila ATCC 9341 as test microorganism. Susceptibility was established by the antimicrobial disc diffusion test. Individual lincomycin plasma concentration-time curves were analysed by a non-compartmental approach. After intravenous administration, volume of distribution, body clearance and elimination half-life were 0.97 L/kg ± 0.15 L/kg, 0.17 L/kg ± 0.06 L/h.kg and 4.20 h ± 1.12 h, respectively. After oral administration, peak plasma concentration, time of maximum plasma concentration and bioavailability were 22.52 μg/mL ± 10.97 μg/mL, 0.80 h ± 0.11 h and 81.78% ± 24.05%, respectively. Two hours after lincomycin administration, skin concentrations were 17.26 μg/mL ± 1.32 μg/mL (intravenous) and 16.58 μg/mL ± 0.90 μg/mL (oral). The corresponding skin: plasma ratios were 2.08 ± 0.47 (intravenous) and 1.84 ± 0.97 (oral). The majority of staphylococci and streptococci tested in this study were susceptible to lincosamides (87.09% and 69.56%, respectively). In conclusion, lincomycin administered orally at the assayed dose showed a good pharmacokinetic profile, with a long elimination half-life and effective skin concentration. Therefore, it could be a good first option for treating skin infections in cats.Fil: Albarellos, Gabriela Alejandra. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; ArgentinaFil: Montoya, Laura. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; ArgentinaFil: Denamiel, Graciela A. A.. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; ArgentinaFil: Passini, Sabrina Mariela. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; ArgentinaFil: Landoni, Maria Fabiana. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; ArgentinaSouth African Veterinary Association2013-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/77377Albarellos, Gabriela Alejandra; Montoya, Laura; Denamiel, Graciela A. A.; Passini, Sabrina Mariela; Landoni, Maria Fabiana; Pharmacokinetics and skin concentrations of lincomycin after intravenous and oral administration to cats; South African Veterinary Association; Journal of the South African Veterinary Association-Tydskrif van die Suid-Afrikaanse Veterinere Vereniging; 84; 1; 10-2013; 1-50038-28092224-9435CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.4102/jsava.v84i1.968info:eu-repo/semantics/altIdentifier/url/https://jsava.co.za/index.php/jsava/article/view/968info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:10:38Zoai:ri.conicet.gov.ar:11336/77377instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:10:38.798CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Pharmacokinetics and skin concentrations of lincomycin after intravenous and oral administration to cats
title Pharmacokinetics and skin concentrations of lincomycin after intravenous and oral administration to cats
spellingShingle Pharmacokinetics and skin concentrations of lincomycin after intravenous and oral administration to cats
Albarellos, Gabriela Alejandra
LINCOMYCIN
PHARMACOKINETICS
SKIN
CAT
title_short Pharmacokinetics and skin concentrations of lincomycin after intravenous and oral administration to cats
title_full Pharmacokinetics and skin concentrations of lincomycin after intravenous and oral administration to cats
title_fullStr Pharmacokinetics and skin concentrations of lincomycin after intravenous and oral administration to cats
title_full_unstemmed Pharmacokinetics and skin concentrations of lincomycin after intravenous and oral administration to cats
title_sort Pharmacokinetics and skin concentrations of lincomycin after intravenous and oral administration to cats
dc.creator.none.fl_str_mv Albarellos, Gabriela Alejandra
Montoya, Laura
Denamiel, Graciela A. A.
Passini, Sabrina Mariela
Landoni, Maria Fabiana
author Albarellos, Gabriela Alejandra
author_facet Albarellos, Gabriela Alejandra
Montoya, Laura
Denamiel, Graciela A. A.
Passini, Sabrina Mariela
Landoni, Maria Fabiana
author_role author
author2 Montoya, Laura
Denamiel, Graciela A. A.
Passini, Sabrina Mariela
Landoni, Maria Fabiana
author2_role author
author
author
author
dc.subject.none.fl_str_mv LINCOMYCIN
PHARMACOKINETICS
SKIN
CAT
topic LINCOMYCIN
PHARMACOKINETICS
SKIN
CAT
purl_subject.fl_str_mv https://purl.org/becyt/ford/4.3
https://purl.org/becyt/ford/4
dc.description.none.fl_txt_mv The aim of the present study was to describe the plasma pharmacokinetic profile and skin concentrations of lincomycin after intravenous administration of a 15% solution and oral administration of 300 mg tablets at a dosing rate of 15 mg/kg to cats. Susceptibility of staphylococci (n = 31) and streptococci (n = 23) strains isolated from clinical cases was also determined. Lincomycin plasma and skin concentrations were determined by microbiological assay using Kocuria rhizophila ATCC 9341 as test microorganism. Susceptibility was established by the antimicrobial disc diffusion test. Individual lincomycin plasma concentration-time curves were analysed by a non-compartmental approach. After intravenous administration, volume of distribution, body clearance and elimination half-life were 0.97 L/kg ± 0.15 L/kg, 0.17 L/kg ± 0.06 L/h.kg and 4.20 h ± 1.12 h, respectively. After oral administration, peak plasma concentration, time of maximum plasma concentration and bioavailability were 22.52 μg/mL ± 10.97 μg/mL, 0.80 h ± 0.11 h and 81.78% ± 24.05%, respectively. Two hours after lincomycin administration, skin concentrations were 17.26 μg/mL ± 1.32 μg/mL (intravenous) and 16.58 μg/mL ± 0.90 μg/mL (oral). The corresponding skin: plasma ratios were 2.08 ± 0.47 (intravenous) and 1.84 ± 0.97 (oral). The majority of staphylococci and streptococci tested in this study were susceptible to lincosamides (87.09% and 69.56%, respectively). In conclusion, lincomycin administered orally at the assayed dose showed a good pharmacokinetic profile, with a long elimination half-life and effective skin concentration. Therefore, it could be a good first option for treating skin infections in cats.
Fil: Albarellos, Gabriela Alejandra. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; Argentina
Fil: Montoya, Laura. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; Argentina
Fil: Denamiel, Graciela A. A.. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; Argentina
Fil: Passini, Sabrina Mariela. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; Argentina
Fil: Landoni, Maria Fabiana. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina
description The aim of the present study was to describe the plasma pharmacokinetic profile and skin concentrations of lincomycin after intravenous administration of a 15% solution and oral administration of 300 mg tablets at a dosing rate of 15 mg/kg to cats. Susceptibility of staphylococci (n = 31) and streptococci (n = 23) strains isolated from clinical cases was also determined. Lincomycin plasma and skin concentrations were determined by microbiological assay using Kocuria rhizophila ATCC 9341 as test microorganism. Susceptibility was established by the antimicrobial disc diffusion test. Individual lincomycin plasma concentration-time curves were analysed by a non-compartmental approach. After intravenous administration, volume of distribution, body clearance and elimination half-life were 0.97 L/kg ± 0.15 L/kg, 0.17 L/kg ± 0.06 L/h.kg and 4.20 h ± 1.12 h, respectively. After oral administration, peak plasma concentration, time of maximum plasma concentration and bioavailability were 22.52 μg/mL ± 10.97 μg/mL, 0.80 h ± 0.11 h and 81.78% ± 24.05%, respectively. Two hours after lincomycin administration, skin concentrations were 17.26 μg/mL ± 1.32 μg/mL (intravenous) and 16.58 μg/mL ± 0.90 μg/mL (oral). The corresponding skin: plasma ratios were 2.08 ± 0.47 (intravenous) and 1.84 ± 0.97 (oral). The majority of staphylococci and streptococci tested in this study were susceptible to lincosamides (87.09% and 69.56%, respectively). In conclusion, lincomycin administered orally at the assayed dose showed a good pharmacokinetic profile, with a long elimination half-life and effective skin concentration. Therefore, it could be a good first option for treating skin infections in cats.
publishDate 2013
dc.date.none.fl_str_mv 2013-10
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/77377
Albarellos, Gabriela Alejandra; Montoya, Laura; Denamiel, Graciela A. A.; Passini, Sabrina Mariela; Landoni, Maria Fabiana; Pharmacokinetics and skin concentrations of lincomycin after intravenous and oral administration to cats; South African Veterinary Association; Journal of the South African Veterinary Association-Tydskrif van die Suid-Afrikaanse Veterinere Vereniging; 84; 1; 10-2013; 1-5
0038-2809
2224-9435
CONICET Digital
CONICET
url http://hdl.handle.net/11336/77377
identifier_str_mv Albarellos, Gabriela Alejandra; Montoya, Laura; Denamiel, Graciela A. A.; Passini, Sabrina Mariela; Landoni, Maria Fabiana; Pharmacokinetics and skin concentrations of lincomycin after intravenous and oral administration to cats; South African Veterinary Association; Journal of the South African Veterinary Association-Tydskrif van die Suid-Afrikaanse Veterinere Vereniging; 84; 1; 10-2013; 1-5
0038-2809
2224-9435
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.4102/jsava.v84i1.968
info:eu-repo/semantics/altIdentifier/url/https://jsava.co.za/index.php/jsava/article/view/968
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv South African Veterinary Association
publisher.none.fl_str_mv South African Veterinary Association
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842270127908716544
score 13.13397

Publicaciones similares